Market Place
Sourcing Support
Enlivex To Unveil Allocetra Phase Iia Data At OARSI 2026 Congress
23 Apr 2026 //
FIRSTWORD PHARMA
Enlivex Secures FDA IND for Allocetra Phase 2b Knee OA Trial
23 Mar 2026 //
GLOBENEWSWIRE
Enlivex Therapeutics Shares To Trade Exclusively On Nasdaq
23 Jan 2026 //
GLOBENEWSWIRE
Enlivex Reports Positive 6-Month Data For Knee Osteoarthritis
24 Nov 2025 //
GLOBENEWSWIRE
Enlivex to Present Ph IIa Allocetra Data in Knee Osteoarthritis
28 Oct 2025 //
GLOBENEWSWIRE
Enlivex CEO Shares Roadmap After Positive Ph 2a Allocetra Data
11 Sep 2025 //
GLOBENEWSWIRE
Enlivex to Present Phase IIa Knee Osteoarthritis Data on August
14 Aug 2025 //
GLOBENEWSWIRE
Enlivex Completes Enrollment in Phase II Trial for Knee Osteoarth
21 Apr 2025 //
GLOBENEWSWIRE
Enlivex Hosts Webinar On Positive Ph1/2 Allocetra Osteoarthritis Data
04 Mar 2025 //
GLOBENEWSWIRE
Enlivex Receives Regulatory Nod For Allocetra TMJ Osteoarthritis Trial
11 Dec 2024 //
GLOBENEWSWIRE
Enlivex Announces Positive Data from Allocetra Trial for Knee OA
03 Dec 2024 //
GLOBENEWSWIRE
Enlivex Doses First Patient in Psoriatic Arthritis Phase I Trial
14 Nov 2024 //
GLOBENEWSWIRE
Enlivex Doses First 10 Patients in Allocetra Knee OA Trial
12 Nov 2024 //
GLOBENEWSWIRE
Enlivex Receives Japanese Patent for Allocetra™ in OA
30 Oct 2024 //
GLOBENEWSWIRE
Enlivex Begins Phase I/II Trial of AllocetraTM in Thumb Osteoa
24 Jun 2024 //
GLOBENEWSWIRE
Enlivex Announces +ve Interim Data From Ph I/II Trial Of Allocetra In Knee OA
17 Jun 2024 //
GLOBENEWSWIRE
Enlivex`s Allocetra Placebo Trial In Thumb Osteoarthritis Authorized
03 Jun 2024 //
GLOBENEWSWIRE
Enlivex Doses First Allocetra Knee Osteoarthritis Patients
22 Apr 2024 //
GLOBENEWSWIRE
Enlivex Authorized for Allocetra Phase I/II Trial in Knee Osteoarthritis
16 Apr 2024 //
GLOBENEWSWIRE
Enlivex’s Stock Plummets 50% on Phase II Sepsis Results for Cell Therapy
13 Apr 2024 //
BIOSPACE
Enlivex Topline Phase 2 Allocetra Results In Sepsis Patients
11 Apr 2024 //
GLOBENEWSWIRE
Enlivex Webcast 4/12 On Phase 2 Allocetra Sepsis Trial Results
11 Apr 2024 //
GLOBENEWSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells
07 Feb 2024 //
GLOBENEWSWIRE
Enlivex Receives Authorization for Initiation of Ph I/II Evaluating Allocetra
17 Jan 2024 //
GLOBENEWSWIRE
Enlivex Announces Completion of Enrollment of Ph II Trial Evaluating Allocetra
20 Dec 2023 //
GLOBENEWSWIRE
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of PII Evaluating Allocetra
31 Jul 2023 //
GLOBENEWSWIRE
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra
08 May 2023 //
GLOBENEWSWIRE
Enlivex Announces Tislelizumab Collaboration, Full Year Financial Results
04 Apr 2023 //
GLOBENEWSWIRE
Enlivex, BeiGene Partner to Evaluate Allocetra/PD-1 Inhibitor Tislelizumab
03 Apr 2023 //
CONTRACT PHARMA
Enlivex Announces Collaboration to Evaluate Combinations of Allocetra & Tislelizumab
03 Apr 2023 //
GLOBENEWSWIRE
Enlivex Announces Issuance of Patent Covering Use of Allocetra to Prevent CRS
15 Feb 2023 //
GLOBENEWSWIRE
